By physician referral or invitation only

Open-label Study of Leniolisib in Pediatric Patients (Aged 1 to 6 Years) with APDS (Activated Phosphoinositide 3-Kinase Delta Syndrome)

This study has 2 purposes: to assess the immediate safety, tolerability, and effectiveness of leniolisib in pediatric patients (aged 1 to 6 years) with activated phosphoinositide 3-kinase delta (PI3Kd) syndrome (APDS). The 2nd purpose is to assess the long term safty and tolerability of leniolisib in the same population.

Age & Gender

1 years ~ 6 years
Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study is recruiting by invitation only.

United States (Nationwide)

Additional Study Information

Principal Investigator

Amika Sood
Pediatrics - Children's Research Institute

Study Type

Clinical or Medical
Interventional

Study Topics

Immune System/Infections

IRB Number

23-1169

ClinicalTrials.gov

NCT05693129

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.